Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LMLN antisense RNA 1 (LMLN-AS1)
- Target
- LMLN-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense lncRNA, Non-protein coding RNA gene
01
Overview
LMLN antisense RNA 1 (LMLN-AS1) is a human long non-coding RNA (lncRNA) gene that is transcribed in the antisense direction relative to the LMLN gene locus on chromosome 3[1]. Unlike protein-coding genes, LMLN-AS1 does not encode a protein and likely functions through RNA-based regulatory mechanisms typical of antisense lncRNA, such as influencing the expression or chromatin state of its sense gene partner or nearby genomic loci[1][2]. LMLN-AS1's functional roles and disease associations have not yet been elucidated; it is annotated in databases as a member of the antisense non-coding RNA class, but lacks experimental literature detailing its biological or pathological significance as of current knowledge[1][3].
- Other names
- LMLN antisense RNA 1 (non-protein coding)LMLN-AS1Ankyrin repeat domain 18A pseudogeneANKRD18DP
02
Mechanism of action
Not applicable. No drug interactions reported, so no mechanism recorded for therapeutics targeting LMLN-AS1. - In general, antisense lncRNAs can act through gene silencing, altering splicing, promoter interference, or chromatin structure changes
03
Biological functions
Likely to modulate the expression of its sense gene (LMLN) through antisense mechanisms (typical for antisense lncRNAs)May participate in transcriptional regulation or chromatin remodeling, but specific functions for LMLN-AS1 are not described in current databases; general lncRNA antisense features include regulation of gene expression, epigenetic modification, and transcriptional interference
04
Disease associations
No direct association reported for LMLN-AS1 with human disease as of nowIn general, lncRNAs and antisense RNAs are increasingly implicated in cancer, neurological diseases, and developmental disordersLMLN-AS1 does not have currently known disease roles in major annotated resources.
Beyond the preview
Go deeper on LMLN antisense RNA 1 (LMLN-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMLN antisense RNA 1 (LMLN-AS1).